]>
IRCT20160511027853N2 IRCT 2020-05-31 Qazvin University of Medical Sciences "Evaluation of the effect of Erythropoietin on Antropometric results";"Evaluation of the effect of Erythropoietin on Edema" Anthropometric Outcome and Edema in Low Birth Weight Infants Treated With Erythropoietin 2020-04-20 anticipated 80 Complete https://irct.ir/trial/47069 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, with a sample size of 80 neonates, 40 balls for the intervention group, and 40 balls for the control group are placed in a lottery container, and then the balls are randomly removed from the container without replacement and the created sequence is recorded. 4 prematurity. Intervention 1: Intervention group: Anthropometric characteristics of infants include birth weight, height, and head circumference. The RETIC and CBCdiff are tested one week after birth. Two weeks after birth, Erythropoietin is given three times a week for a month (12 times). The 2000 u Erythropoietin ampule produced by Sinagen Pharmaceutical Company is used, 100 units per kilogram for each baby. The tests are re-checked two weeks after the last Erythropoietin injection. In the control group, without drug injection, the tests are performed at 14 and 40 days of age. After the injection, the injection side-effects and edema are examined. Finally, the anthropometric tests and criteria are compared before and after the intervention. If Erythropoietin is effective, the primary consequences are increased in neonatal improvements, such as sucking and swallowing power, secondary outcomes, including; improved neonatal general condition, prevention of neonatal apnea, improved neonatal anthropometric criteria, and reduced edema. Intervention 2: Control group: These babies are prone to infection and malaise due to their pre-term. At the discretion of the Clinical Ethics Committee, no placebo is used for this group and they receive routine treatment. Yes - There is a plan to make this available What will be shared: All potential data can be shared after people have not been identified When: Start accessing data immediately after the article is published To whom: It will only be available to researchers working in academic and scientific institutions Conditions: There are no other conditions Where to obtain: Refer to Dr. Seyed Hoshyar Mojabi How to obtain: Giving an email to Dr. Seyed Hoshyar Mojabi and answering within a week at most Comments:
public Farahnaz Mohammadkhaniha
Kosar Educational and Medical Center،Taleghani Ave،Qazvin
Qazvin Iran (Islamic Republic of) 3415613176 +98 28 3323 6380 farahnaz.mohammadkhaniha@gmail.com Qazvin University of Medical Sciences scientific Dr. Seyed Hoshyar Mojabi
Kosar Educational and Medical Center, Taleghani Ave,Qazvin
Qazvin Iran (Islamic Republic of) 3415613176 +98 28 3323 6380 mogabi1355@gmail.com Qazvin University of Medical Sciences Iran (Islamic Republic of) Premature birth with gestational age at birth less than 35 weeks Birth weight less than 2000 grams No illness (healthy babies who experience no problems or sickness in the first week of birth). 7 days 40 days Both Congenital anomalies depression thrombocytopenia diastolic pressure greater than 60 mmHg shock hydrops fetalis threesomes seizures hemolytic diseases. Treatment - Drugs Other Intervention group: Anthropometric characteristics of infants include birth weight, height, and head circumference. The RETIC and CBCdiff are tested one week after birth. Two weeks after birth, Erythropoietin is given three times a week for a month (12 times). The 2000 u Erythropoietin ampule produced by Sinagen Pharmaceutical Company is used, 100 units per kilogram for each baby. The tests are re-checked two weeks after the last Erythropoietin injection. In the control group, without drug injection, the tests are performed at 14 and 40 days of age. After the injection, the injection side-effects and edema are examined. Finally, the anthropometric tests and criteria are compared before and after the intervention. If Erythropoietin is effective, the primary consequences are increased in neonatal improvements, such as sucking and swallowing power, secondary outcomes, including; improved neonatal general condition, prevention of neonatal apnea, improved neonatal anthropometric criteria, and reduced edema. Control group: These babies are prone to infection and malaise due to their pre-term. At the discretion of the Clinical Ethics Committee, no placebo is used for this group and they receive routine treatment. Around the head. Timepoint: Birth, one week after birth, two weeks after birth, forty days after birth. Method of measurement: Tape Measure. Weight. Timepoint: Birth, one week after birth, two weeks after birth, forty days after birth. Method of measurement: Baby digital scale with SCEA brand, Model 374, which weighs 5 grams. Edema. Timepoint: daily. Method of measurement: Pitting Edema Grading Scale. Height. Timepoint: Birth day and forty day of birth. Method of measurement: Tape Measure. The general condition of the neonate. Timepoint: every hour. Method of measurement: General examination of infants in terms of tachypnea, cyanosis, lactation, excretion, weight gain. Qazvin University of Medical Sciences Approved 2019-12-14 Ethics committee of Qazvin University of Medical Sciences Kosar Hospital, Taleqani Ave,Qazvin,Iran Qazvin Qazvin Iran (Islamic Republic of)